PHARMACY

CCA, AIMp join forces to speak for British chains

BY Adam Kraemer

NOTTINGHAMSHIRE, England The Company Chemists Association and the Association of Independent Multiples announced Monday that they are establishing a joint venture to undertake policy development and representation on behalf of the membership of the two bodies. “Multiples” is the U.K. equivalent of U.S. “chain stores.”

“Pharmacy representation is going through a period of unprecedented change. Multiple pharmacy is becoming an increasingly significant player in the UK community pharmacy sector,” observed Digby Emson, the chairman of CCA. “Over the last few years, it has become clear that AIMp and the CCA share a lot of common ground.”

The collaboration will be formally structured as a jointly owned company, “The CCA & AIMp Ltd.,” which will draw resources and manpower from both organizations to undertake a jointly established work program, focused on the development of shared policy positions and representation of the multiple perspective within pharmacy and externally with key health care stakeholders.

“This is an opportunity for both organizations to build on their strategic fit with much closer collaboration. Together, CCA and AIMp represent over 60 percent of the market. We have seen over the last year that through collaboration, we both benefit and have increased influence,” said Steve Williams, the chairman of AIMp. “AIMp and the CCA have different roots, and will continue as organizations in their own right, but wherever possible in the future we will be speaking, through CCA & AIMp Ltd, with one voice.”

“This joint venture provides a vehicle for us to collaborate more closely and to ensure that there is stronger voice for multiple pharmacy in both NHS and professional policy making moving forward,” added Emson. “We see this development as a win-win for both our organizations—and the sector as a whole. “

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

ACC speaks out in favor of waiting for results of further Vytorin trials

BY Drew Buono

WASHINGTON With all the fallout from the ENHANCE trial regarding Merck and Schering-Plough’s cholesterol drug Vytorin, there is one positive show of support for the drug and it comes from the American College of Cardiology, according to published reports.

The ACC issued a statement saying that “major clinical decisions [should] not be made on the basis of the ENHANCE study alone [as it deserves] serious thought and follow-up.” The overall incidence rates of cardiac events were nearly identical between both treatment groups and both were generally well tolerated, the statement said, so “there should be no reason for patients to panic.” It added that the ENHANCE trial “is an imaging study and not a clinical-outcome study,” and that conclusions should not be made until three large clinical-outcome trials are presented within the next two to three years.

But, there are still many who feel the drug is unsafe and has been since it was put on the market. Sidney Wolfe, director of Health Research Group at Public Citizen, said that “we first warned against using Vytorin in December 2004” and suggested people should wait at least seven years before taking the treatment as it was not a “breakthrough” drug.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

GSK, TB Alliance renew partnership for tuberculosis treatment

BY Drew Buono

LONDON and NEW YORK GlaxoSmithKline and the Global Alliance for TB Drug Development have renewed their joint research program that is designed to improve the treatment of tuberculosis. The collaboration began in 2004 and currently includes some projects that may produce new medicines to attack Mycobacterium tuberculosis, which causes tuberculosis.

The deal has been extended for an additional three years to research tuberculosis and malaria. So far under the deal, the collaboration has seen two drug discovery projects, out of five, in non-clinical studies to have potential benefits in fighting persistent forms of mycobacterium tuberculosis and thereby offer better chances of shortening treatment duration, which currently takes about six months to complete.

“We are encouraged by the success of our pioneering work with GSK, which has nearly doubled the number of TB drug discovery projects in our pipeline,” said Mel Spigelman, TB Alliance director of research and development. “This collaboration is advancing the TB Alliance’s mission to develop revolutionary, faster and better TB treatment regimens by exploring new ways to attack the disease.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?